Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

1.220 +0.030 (+2.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 118,434
Open 1.190
Bid (Size) 1.180 (800)
Ask (Size) 1.230 (800)
Prev. Close 1.190
Today's Range 1.180 - 1.265
52wk Range 1.050 - 3.100
Shares Outstanding 34,380,971
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Receives FDA IND Clearance for Telomir-Zn in Triple-Negative Breast Cancer
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
Via ACCESS Newswire

Performance

YTD
-9.0%
-9.0%
1 Month
-17.6%
-17.6%
3 Month
+6.1%
+6.1%
6 Month
-12.9%
-12.9%
1 Year
-52.0%
-52.0%

More News

Read More
MissionIRNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Closes TELI Acquisition, Secures Global Rights to Telomir-1
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
Via ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Submits IND for TNBC Candidate Telomir-1
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
Via ACCESS Newswire
BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Iron-Dependent Tumor Cell Mortality in TNBC Models
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
Via ACCESS Newswire
BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports New Cellular Data Demonstrating Coordinated Intracellular Zinc Increase and Iron Reduction With Telomir-Zn
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
Via ACCESS Newswire
MissionIRNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Positive Telomir-1 Results In TNBC Zebrafish Xenograft Study
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
Via ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Favorable IND-Enabling GLP Safety Results for Telomir-1
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
Via ACCESS Newswire
News headline image
TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death ↗
Via Stocktwits
News headline image
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga

Frequently Asked Questions

Is Telomir Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Telomir Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Telomir Pharmaceuticals, Inc. - Common Stock trade on?
Telomir Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock is TELO on the Nasdaq Stock Market
What is the current price of Telomir Pharmaceuticals, Inc. - Common Stock?
The current price of Telomir Pharmaceuticals, Inc. - Common Stock is 1.220
When was Telomir Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Telomir Pharmaceuticals, Inc. - Common Stock was at 05/19/26 04:00 PM ET
What is the market capitalization of Telomir Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Telomir Pharmaceuticals, Inc. - Common Stock is 41.94M
How many shares of Telomir Pharmaceuticals, Inc. - Common Stock are outstanding?
Telomir Pharmaceuticals, Inc. - Common Stock has 42M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.